Year: 2019

VANCOUVER, Colombie-Britannique, 12 déc. 2019 (GLOBE NEWSWIRE) — AgraFlora Organics International Inc.  (« AgraFlora » ou la « Société ») (CSE : AGRA) (Frankfurt: PU31) (OTCPK : AGFAF) une société internationale de cannabis diversifiée et axée sur la croissance est heureuse d’annoncer que sa filiale au Royaume-Uni, Farmako Limited, a terminé son processus d’inspection dans le but d’obtenir une licence relative aux drogues contrôlées au Royaume-Uni.Farmako Limited avait déjà obtenu la certification pour sa conformité aux bonnes pratiques de distribution (« BPD ») ainsi qu’une autorisation pour la distribution en gros (« ADG ») de médicaments, y compris le cannabis médical, à l’été 2019 après avoir terminé une inspection réussie par le Medicines and Healthcare Products Regulatory Agency (le « MRHA ») du Royaume-Uni plus tôt cette...

12. december 2019Meddelelse nr. 300   INDKALDELSE OG DE FULDSTÆNDIGE FORSLAGFor den ekstraordinære generalforsamling i Rovsing A/SBestyrelsen i Rovsing A/S indkalder hermed til ekstraordinær generalforsamling i Rovsing A/S (“Selskabet”)Mandag, den 6. januar 2020 kl. 12.00hos Rovsing A/S, Dyregårdsvej 2, 2740 Skovlundemed følgende dagsorden: 1.                  Forslag om kapitalnedsættelse samt konsekvensændring af Selskabets vedtægter  Ad 1:      Forslag om kapitalnedsættelse samt konsekvensændring af Selskabets vedtægterPå den ordinære generalforsamling den 21. oktober 2019 blev det besluttet at gennemføre en aktiesammenlægning/omvendt aktiesplit af alle aktier udstedt af Selskabet i forholdet 1.000:1, ved opskrivning af den nominelle værdi pr. aktie fra DKK 0,05 til DKK 50,0 pr. aktie.Som følge af gennemførelsen heraf besidder...

Reference is made to the announcement on 12 December 2019. Sbanken ASA has today issued a NOK 100 million Additional Tier 1 bond with a coupon equal to 3 months NIBOR + 3.15 percentage points. In addition the bank has issued a NOK 125 million Subordinated Tier 2 bond with a coupon equal to 3 months NIBOR + 1.30 percentage points.Settlement date for both bonds will be 19 December 2019, and both bond issues will be applied for listing at Nordic ABM.The transactions are approved by the annual general meeting and the Norwegian FSA.DNB Markets was sole arranger of the two issues.Contact details,Øyvind Telle, Head of Treasury, Sbanken ASA, +47 916 88 704Jesper Hatletveit, Head of IR, Sbanken ASA, +47 959 40 045This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act

Det vises til børsmelding den 12. desember 2019. Sbanken ASA har i dag utstedt en fondsobligasjon pålydende NOK 100 millioner med en kupong rente tilsvarende 3 måneders NIBOR + 3,15 prosentpoeng. I tillegg har banken utstedt et ansvarlig lån på NOK 125 millioner med en kupongrente tilsvarende 3 måneders NIBOR + 1,30 prosentpoeng.Begge lån har innbetalingsdato 19 desember 2019. Lånene vil bli søkt notert på Nordic ABM.Låneutstedelsene er godkjent av generalforsamlingen og tillatelse er gitt av Finanstilsynet.DNB Markets var tilrettelegger av utstedelsene.Kontaktdetaljer,Øyvind Telle, Head of Treasury, Sbanken ASA, +47 916 88 704Jesper Hatletveit, Investor Relations, Sbanken ASA, +47 959 40 045Denne opplysningen er informasjonspliktig etter verdipapirhandelloven §5-12

All arms met all primary endpoints against baseline, showing strong efficacy, safety, and rapid speed of onsetHowever, MED2005 did not meet primary endpoints versus placeboBased on statistically significant, results compared against baseline, Futura intends to discuss a potential medical device regulatory approval pathway with the U.S. Food and Drug AdministrationNewly filed patent application has potential to extend protection of DermaSys® until 2039GUILDFORD, England, Dec. 12, 2019 (GLOBE NEWSWIRE) — Futura Medical plc (AIM: FUM) (the “Company”), a pharmaceutical company developing a portfolio of innovative products based on its proprietary transdermal DermaSys® drug delivery technology currently focused on sexual health and pain, today announced  top-line results from the European Phase 3 study, “FM57” of its lead product candidate,...

Hørsholm, Denmark, 12 December 2019 – As previously communicated by Oncology Venture A/S (“OV” or the “Company”), OV is concluding the fully subscribed rights issue and as part of this process welcomes Mr Mats Gabrielsson as a major shareholder to the Company.The investment is done through the Gabrielsson family office, Gabrielsson Invest AB (and subsidiaries), which for over 18 months has been and will continue to be a financier and corporate lender to the Company while also being a shareholder. The new investment substantially increases Mr Gabrielsson’s shareholding in the Company, which Mr Gabrielsson considers to be one of the currently most exciting companies on the market for cancer treatment. After completion of the capital increase in respect of the rights issue, Mr Gabrielsson will control just under 10 % of the shares.”I have...

TORONTO, Dec. 12, 2019 (GLOBE NEWSWIRE) — Star Navigation Systems Group Ltd. (CSE: SNA) (CSE: SNA.CN) (OTCQB: SNAVF) (“Star” or the “Company”) responds to the latest illegal and disruptive tactics of a dissident shareholder group (the “Dissidents”) and confirms that no special meeting of shareholders of the Company was held on December 11, 2019. The Company also confirms that the press release filed by the Dissidents on December 11, 2019, which falsely alleges that certain persons have been elected and appointed as directors and officers, respectively, was not authorized by Star and no such election or appointments have been made. The reckless and illegal acts of the Dissidents continue to jeopardize the Company’s operation.The Company has commenced legal action to prohibit the Dissidents from engaging in any further illegal...

MONTRÉAL, Dec. 12, 2019 (GLOBE NEWSWIRE) — IBEX Technologies Inc. (“IBEX” or the “Company”) (TSX Venture: IBT) today reported its financial results for the three months ended October 31, 2019.“We were pleased to see that sales returned to the year ago level, and that the earnings-effect of the closure of the Iowa facility are beginning to be realized somewhat earlier than predicted”, said Paul Baehr, IBEX President & CEO. “We still expect to see wide variations in quarter to quarter sales as in the past but are still projecting a modest positive EBITDA  for Fiscal 2020 with sales similar to Fiscal 2019.”Note: All figures are in Canadian dollars unless otherwise stated. The Company’s audited consolidated financial statements for the year ended July 31, 2019 and the accompanying notes and the related management’s discussion and...

PHILADELPHIA, Dec. 12, 2019 (GLOBE NEWSWIRE) — Hersha Hospitality Trust (NYSE: HT) (“Hersha” or the “Company”), owner of high-quality upscale, luxury and lifestyle hotels in urban gateway markets and resort destinations, today announced that its Board of Trustees declared a cash dividend of $0.4297 per Series C Preferred Share, $0.40625 per Series D Preferred Share, and $0.40625 per Series E Preferred Share for the fourth quarter ending December 31, 2019. The preferred share dividends are payable January 15, 2020 to holders of record as of January 1, 2020.The Board of Trustees also declared cash dividends totaling $0.28 per common share and per limited partnership unit for the fourth quarter ending December 31, 2019. These common share dividends and limited partnership unit distributions are payable January 15, 2020 to holders of...

CALGARY, Alberta, Dec. 12, 2019 (GLOBE NEWSWIRE) — E Split Corp. (TSX: ENS and ENS.PR.A) (the “Fund”) is pleased to announce that a distribution for December 2019 will be payable to Class A shareholders as follows: